Ubiquitin E3 ligase WWP1 as an oncogenic factor in human prostate cancer

Oncogene

Volumn 26, Issue 16, 2007, Pages 2386-2394

  Chen, C ^a,b   Sun, X ^a   Guo, P ^a   Dong, X Y ^a   Sethi, P ^a   Zhou, W ^a   Zhou, Z ^b   Petros, J ^a,c   Frierson Jr , H F ^d   Vessella, R L ^e   Atfi, A ^f   Dong, J T ^a,g  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c ATLANTA VA MEDICAL CENTER   (United States)

^d UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f HÔPITAL SAINT ANTOINE   (France)

^g NANKAI UNIVERSITY   (China)

Author keywords

Amplification; KLF5; Overexpression; Prostate cancer; TGF ; WWP1

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA; UBIQUITIN PROTEIN LIGASE E3;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; GENE; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MITOSIS INHIBITION; PRIORITY JOURNAL; PROSTATE CANCER; WWP1 GENE; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 8; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PROSTATIC NEOPLASMS; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA; TRANSPLANTATION, HETEROLOGOUS; UBIQUITIN-PROTEIN LIGASES;

EID: 34147185239     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210021     Document Type: Article

References (35)

1. Chen C, Bhalala HV, Qiao H, Dong JT. (2002). A possible tumor suppressor role of the KLF5 transcription factor in human breast cancer. Oncogene 21: 6567-6572.
2. Chen C, Bhalala HV, Vessella RL, Dong JT. (2003a). KLF5 is frequently deleted and down-regulated but rarely mutated in prostate cancer. Prostate 55: 81-88.
3. Chen C, Hyytinen ER, Sun X, Helin HJ, Koivisto PA, Frierson HF et al. (2003b). Deletion, mutation, and loss of expression of KLF6 in human prostate cancer. Am J Pathol 162: 1349-1354.
4. Chen C, Sun X, Guo P, Dong XY, Sethi P, Cheng X et al. (2005a). Human Kruppel-like factor 5 is a target of the E3 ubiquitin ligase WWP1 for proteolysis in epithelial cells. J Biol Chem 280: 41553-41561.
5. Chen C, Sun X, Ran Q, Wilkinson KD, Murphy TJ, Simons JW et al. (2005b). Ubiquitin-proteasome degradation of KLF5 transcription factor in cancer and untransformed epithelial cells. Oncogene 24: 3319-3327.
6. Danielpour D. (2005). Functions and regulation of transforming growth factor-beta (TGF-beta) in the prostate. Eur J Cancer 41: 846-857.
7. Dong JT. (2006). Prevalent mutations in prostate cancer. J Cell Biochem 97: 433-447.
8. Dong JT, Chen C, Stultz BG, Isaacs JT, Frierson Jr HF. (2000). Deletion at 13q21 is associated with aggressive prostate cancers. Cancer Res 60: 3880-3883.
9. Drobnjak M, Melamed J, Taneja S, Melzer K, Wieczorek R, Levinson B et al. (2003). Altered expression of p27 and Skp2 proteins in prostate cancer of African-American patients. Clin Cancer Res 9: 2613-2619.
10. Flasza M, Gorman P, Roylance R, Canfield AE, Baron M. (2002). Alternative splicing determines the domain structure of WWP1, a Nedd4 family protein. Biochem Biophys Res Commun 290: 431-437.
11. Gu Z, Rubin MA, Yang Y, Deprimo SE, Zhao H, Horvath S et al. (2005). Reg IV: a promising marker of hormone refractory metastatic prostate cancer. Clin Cancer Res 11: 2237-2243.
12. Ingham RJ, Gish G, Pawson T. (2004). The Nedd4 family of E3 ubiquitin ligases: functional diversity within a common modular architecture. Oncogene 23: 1972-1984.
13. Kim IY, Ahn HJ, Zelner DJ, Shaw JW, Sensibar JA, Kim JH et al. (1996). Genetic change in transforming growth factor beta (TGF-beta) receptor type I gene correlates with insensitivity to TGF-beta 1 in human prostate cancer cells. Cancer Res 56: 44-48.
14. Komuro A, Imamura T, Saitoh M, Yoshida Y, Yamori T, Miyazono K et al. (2004). Negative regulation of transforming growth factor-beta (TGF-beta) signaling by WW domain-containing protein 1 (WWP1). Oncogene 23: 6914-6923.
15. Leite KR, Franco MF, Srougi M, Nesrallah LJ, Nesrallah A, Bevilacqua RG et al. (2001). Abnormal expression of MDM2 in prostate carcinoma. Mod Pathol 14: 428-436.
16. Lu L, Schulz H, Wolf DA. (2002). The F-box protein SKP2 mediates androgen control of p27 stability in LNCaP human prostate cancer cells. BMC Cell Biol 3: 22.
17. Malbert-Colas L, Fay M, Cluzeaud F, Blot-Chabaud M, Farman N, Dhermy D et al. (2003). Differential expression and localisation of WWP1, a Nedd4-like protein, in epithelia. Pflugers Arch 447: 35-43.
18. Massague J, Blain SW, Lo RS. (2000). TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 103: 295-309.
19. Moren A, Imamura T, Miyazono K, Heldin CH, Moustakas A. (2005). Degradation of the tumor suppressor Smad4 by WW and HECT-domain ubiquitin ligases. J Biol Chem 280: 22115-22123.
20. Mu Z, Hachem P, Agrawal S, Pollack A. (2004). Antisense MDM2 oligonucleotides restore the apoptotic response of prostate cancer cells to androgen deprivation. Prostate 60: 187-196.
21. Nupponen NN, Kakkola L, Koivisto P, Visakorpi T. (1998). Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol 153: 141-148.
22. Pickart CM. (2001). Mechanisms underlying ubiquitination. Annu Rev Biochem 70: 503-533.
23. Porkka K, Saramaki O, Tanner M, Visakorpi T. (2002). Amplification and overexpression of Elongin C gene discovered in prostate cancer by cDNA microarrays. Lab Invest 82: 629-637.
24. Roberts AB, Wakefield LM. (2003). The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci USA 100: 8621-8623.
25. Rubin MA, Varambally S, Beroukhim R, Tomlins SA, Rhodes DR, Paris PL et al. (2004). Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer. Cancer Res 64: 3814-3822.
26. Seo SR, Lallemand F, Ferrand N, Pessah M, L'Hoste S, Camonis J et al. (2004). The novel E3 ubiquitin ligase Tiul1 associates with TGIF to target Smad2 for degradation. EMBO J 23: 3780-3792.
27. Sun SY, Yue P, Dawson MI, Shroot B, Michel S, Lamph WW et al. (1997). Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells. Cancer Res 57: 4931-4939.
28. Sun X, Frierson HF, Chen C, Li C, Ran Q, Otto KB et al. (2005). Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer. Nat Genet 37: 407-412.
29. van Dekken H, Alers JC, Damen IA, Vissers KJ, Krijtenburg PJ, Hoedemaeker RF et al. (2003). Genetic evaluation of localized prostate cancer in a cohort of forty patients: gain of distal 8q discriminates between progressors and nonprogressors. Lab Invest 83: 789-796.
30. van der Poel HG. (2004). Mammalian target of rapamycin and 3-phosphatidylinositol 3-kinase pathway inhibition enhances growth inhibition of transforming growth factor-beta1 in prostate cancer cells. J Urol 172: 1333-1337.
31. Verdecia MA, Joazeiro CA, Wells NJ, Ferrer JL, Bowman ME, Hunter T et al. (2003). Conformational flexibility underlies ubiquitin ligation mediated by the WWP1 HECT domain E3 ligase. Mol Cell 11: 249-259.
32. Wang R, Xu J, Saramaki O, Visakorpi T, Sutherland WM, Zhou J et al. (2004). PrLZ, a novel prostate-specific and androgen-responsive gene of the TPD52 family, amplified in chromosome 8q21.1 and overexpressed in human prostate cancer. Cancer Res 64: 1589-1594.
33. Zhang X, Srinivasan SV, Lingrel JB. (2004). WWP1-dependent ubiquitination and degradation of the lung Kruppel-like factor, KLF2. Biochem Biophys Res Commun 316: 139-148.
34. Zhang Z, Li M, Wang H, Agrawal S, Zhang R. (2003). Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci USA 100: 11636-11641.
35. Zitzelsberger H, Kulka U, Lehmann L, Walch A, Smida J, Aubele M et al. (1998). Genetic heterogeneity in a prostatic carcinoma and associated prostatic intraepithelial neoplasia as demonstrated by combined use of laser-microdissection, degenerate oligonucleotide primed PCR and comparative genomic hybridization. Virchows Arch 433: 297-304.